Plasma Proteins
Plasma Proteins Innovation Platform
As a company driven by its promise to patients, we are excited about our further collaboration with PreviPharma, which seeks to identify new plasma proteins for the treatment of diseases with high unmet medical need.
Hematology, infectious disease, gastrointestinal indications, neurology, and inflammation diseases.
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
Possible for sharing mutual goals of providing high tech to reduce antibiotic dosages.
We are a small company located in Mannheim that aims for the treatment of diseases with high unmet medical need.
PreviPharma’s MIP program is a convincing approach in addressing unmet medical need and bears an impressive opportunity on finding new paths combating AMR.